dr. hirsch discusses the role of next-generation egfr inhibitors
Published 10 years ago • 111 plays • Length 1:32Download video MP4
Download video MP3
Similar videos
-
6:14
third-generation egfr inhibitors in nsclc
-
6:37
impressive findings for next-generation egfr inhibitors
-
3:40
next-generation egfr inhibitors in patients with non-t790m resistance
-
1:25
dr. halmos on the impact of egfr inhibitors on the treatment of lung cancer
-
21:41
beyond erlotinib: are second generation egfr inhibitors better or simply newer?
-
0:59
dr. west on emerging changes in the field of egfr-mutant nsclc
-
7:31
newer egfr inhibitors in nsclc
-
8:37
egfr mechanisms of resistance
-
0:52
selecting egfr tyrosine kinase inhibitors for egfr-mutant lung cancer
-
1:47
dr. scagliotti on mechanisms of resistance to egfr tkis
-
3:15
does the specific egfr mutation matter when choosing an oral egfr inhibitor?
-
20:35
tki-resistant egfr-mutant nsclc
-
3:07
third generation egfr tkis for acquired resistance
-
1:48
dr. fred hirsch on next steps for necitumumab in nsclc
-
27:37
next generation egfr inhibitors for mutations and disease
-
18:06
egfr inhibitors in mutation ( ) patients: current therapeutic strategies in the frontline setting
-
3:15
how do we make egfr inhibitors work better for patients
-
3:16
where do we go next with egfr inhibitors?
-
1:14
dr. david spigel discusses the evolving non-small cell lung cancer treatment landscape